跳至主要内容
临床试验/NCT00279721
NCT00279721已完成2 期

Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

Alberta Health services0 个研究点目标入组 40 人开始时间: 2006年1月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
40
主要终点
toxicity according to RTOG criteria

研究概览

简要总结

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

详细描述

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence

排除标准

  • medullary or anaplastic thyroid cancer, unresectable

结局指标

主要结局

toxicity according to RTOG criteria

locoregional control

次要结局

未报告次要终点

研究者

申办方类型
Other

相似试验